Hematologic Malignancies Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||921976|
|出版日期||內容資訊||英文 111 Pages
|惡性血液疾病治療的全球市場:成長率，趨勢及預測 Hematologic Malignancies Treatment Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 111 Pages||
The hematologic malignancies treatment market is predicted to grow with a CAGR of nearly 10.5% during the forecast period. The major factors attributing to the growth of the hematologic malignancies treatment market are the growing incidence of blood cancer, increasing emphasis on the development of new treatments push the growth of hematologic malignancies treatment market.
According to the National Foundation for Cancer Research(NFCR), in 2017, an estimated 58,300 people are likely to die as a result of blood cancer. Furthermore, the increasing awareness about the possibility of early diagnosis of these cancers and the rising approvals for the new drugs of the treatment are other major factors for the market growth. However, the high cost of the medication involved in the treatment is the major restraint to the growth of the market.
According to the scope of the report, hematologic malignancies are forms of cancer that start in the cells of blood-producing tissue, such as the bone marrow, or in the cells of the immune system. This report is segmented by Disease condition, Therapy, End User and Geography.
Chemotherapy is the leading segment of the Hematologic Malignancies Market
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall hematologic malignancies market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of blood cancer patients in the region, established healthcare infrastructure, and availability of branded drugs are some of the key factors accountable for its large share in the market. According to Global Cancer Observatory, in 2018, 18.4% of the world's multiple myeloma cases were of the North American population. The increasing blood cancer cases in the region is a major driving factor for the growth of the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth.
The hematologic malignancies market is moderately consolidated and consists of several major players. Most of the major players are focusing on growing their businesses in developing regions to boost their market share. Furthermore, they are implementing strategies like mergers & acquisitions and new product development. Some of the companies which are currently dominating the market are Pfizer, Inc.; F. Hoffmann-LA Roche ltd; Sanofi S.A.; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; GlaxoSmithKline PLC; Celgene Corporation; Johnson & Johnson Services, Inc.; and Takeda Pharmaceutical Co., Ltd.